Evidence map›Paper›PMID 40375696›Full record

ReviewCurrent drug targets2025

Therapeutic Aspects of Melatonin-sirtuin Crosstalk: An Updated Review of Current Data Based on Cellular Mechanisms.

Azam Hosseinzadeh, Farnoosh Seirafianpour, Mohammad Sheibani, Maryam Taheri, Ali J Naeini, Russel J Reiter, Saeed Mehrzadi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Azam HosseinzadehRazi Drug Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Farnoosh SeirafianpourRazi Drug Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran.ORCID 0000-0003-3794-6206
Mohammad SheibaniRazi Drug Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Maryam TaheriMedical School, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Ali J NaeiniRazi Drug Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Russel J ReiterDepartment of Cellular and Structural Biology, The University of Texas Health Science Center, San Antonio, TX, USA.
Saeed MehrzadiRazi Drug Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melatonin, a master regulator of circadian rhythms and diverse physiological processes, exhibits complex interactions with various molecules. Sirtuins, a family of histone deacetylases, are key players in aging, stress responses, and metabolism and represent a critical target for melatonin. This review explores the multifaceted functions of melatonin and sirtuins, delving into the molecular mechanisms of their interaction. We further examine the impact of this synergy on various pathologies across different organs. Studies suggest that melatonin modulates SIRT1 and SIRT3 signaling pathways, offering protection in neurodegenerative, cardiovascular, skeletal, and pulmonary diseases, as well as renal and hepatic dysfunction. Additionally, melatonin-sirtuin interactions have been implicated in mitigating cancer development and promoting health in the female and male reproductive systems. Notably, the majority of studies across these systems demonstrate melatonin's ability to regulate SIRT1 and SIRT3 signaling, thereby alleviating associated pathologies. In conclusion, the intricate interplay between melatonin and, particularly, SIRT1 and SIRT3 emerges as a crucial modulator of diverse signaling pathways, with promising therapeutic implications for a wide range of diseases.

Indexed as

MelatoninSirtuinsAnimalsCircadian RhythmHumansSignal TransductionSirtuin 1Sirtuin 3MelatoninSirtuin 1Sirtuin 3Sirtuinsagingcancercircadian rhythmMelatoninneurodegenerationsignaling pathways.SIRT1SIRT3sirtuins family

Identifiers

PMID40375696

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.